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A recurring motto from the Tony Blair government in the UK was “Education, 
Education, Education.” An appropriate exhortation for the biomedical sciences 
would be “Standardization, Standardization, Standardization.” Inevitably, the 
two go hand in hand, and the challenge we face is how to encourage researchers 
to comply with existing or emerging standard terminologies and nomenclatures. 
This is both an educational and a regulatory task, one in which it is vital to suc-
ceed if we are to efficiently and accurately share and use the huge volume of 
data emerging in the biosciences.
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Investigators in the fields of medicine 
and biomedical research communicate 
effectively, primarily through the use 
of specialized and defined standard 
terminology (Becker, 1959; Brown et 
al., 2007; Friedman, 1955; Jackson, 
2001; Porter, 2006; Taylor, 2006). It has 
remained fluid over time to accommo-
date new discoveries and technologi-
cal innovations but remains the key to 
denoting advances in science. Within 
the field of dermatology, a committee 
has functioned for decades to standard-
ize nomenclature (Becker, 1959). The 
Journal of Investigative Dermatology 
and other publications in the field 
should insist on strict adherence to the 
most current dermatological nomen-
clature to maintain the high esteem of 
members in the field.
Similar efforts for standardization of 
nomenclature are currently under way 
concerning the pathology of the labora-
tory mouse, now the preeminent model 
system for human disease (Rosenthal 
and Brown, 2007). Because this compli-
cated effort covers all organ systems and 
merges veterinary and human medical 
terminology, various panels have been 
formed to address this issue. For cancer, 
the National Cancer Institute’s Mouse 
Models for Human Cancer Consortium 
created panels of specialists to review 
mouse models for human cancer by 
organ system to develop a consensus 
nomenclature (http://emice.nci.nih.gov/
emice; Cardiff et al., 2000; Kogan et al., 
2002; Nikitin et al., 2004; Shappell et 
al., 2004). A more extensive website, 
the Mouse Tumor Biology Database 
(http://tumor.informatics.jax.org), incor-
porates the mouse genetic literature 
with images of all types of cancer arising 
either spontaneously in mice of inbred 
strains or as a consequence of genetic 
engineering (Bult et al., 2006; Naf et al., 
2002). For general mouse pathology, an 
international consortium was formed 
to develop MPATH, an evolving and 
expanding ontology of mouse pathol-
ogy terms. The consortium is linked to 
a large image database (http://www.
Pathbase.net). These online resources 
are supplemented by highly specialized 
residential training courses and intern-
ship programs (Sundberg et al., 2007), 
but even with these opportunities, a sig-
nificant gap remains between demand 
and availability of appropriately trained 
pathologists (Schofield et al., 2009).
The second annual meeting of 
Coordination and Sustainability of Inter- 
national Mouse Informatics Re sources 
(http://www.casimir.org.uk), held at the 
Nobel Forum, Stockholm, Sweden, 
2–3 December 2008, focused on the 
topic “One Medicine, One Pathology,” 
with the goal of coordinating data 
collection, nomenclature, and com-
parative pathology among various dis-
ciplines (Sundberg and Schofield, in 
press). These approaches refine existing 
nomenclature systems developed over 
the previous two centuries, with which 
all medically trained scientists are 
familiar. Researchers should use these 
online resources to double-check inter-
pretations and standardize the results 
described in their publications. To that 
end, databases are now available that 
provide a “virtual second opinion” 
for mouse pathology nomenclature, 
with links to photomicrographs (http://
research.jax.org/faculty/sundberg/
index.html; Sundberg et al., in press; 
Sundberg et al., 2008).
A larger and far more serious nomen-
clature issue involves genetic terminol-
ogy, an area in which few have been 
trained. Rules for genetic nomencla-
ture were devised in 1919, when the 
American Society of Naturalists appoint-
ed a Committee on Genetic Form and 
Nomenclature, with CC Little as chair-
man (Little, 1921). As they applied to 
the mouse, these rules were published 
in 1940 by Dunn, Grueneberg, and 
Snell (Dunn et al., 1940). Subsequently, 
the International Committee for 
Standardized Genetic Nomenclature in 
Mice (Green et al., 1963) was formed 
to standardize nomenclature for inbred, 
congenic, and recombinant inbred 
strains as well as mutant locus/gene 
symbols. Investigators proposed new 
names for mutant mouse strains and 
stocks (and later for genes) to this com-
mittee, and unique names and symbols 
were assigned to prevent ambiguity. 
Unfortunately, journal editors have been 
slow to require authors to adhere to this 
system, creating major problems. Today, 
with the advent of genetic engineering 
and large-scale mutagenesis projects, 
multiple allelic mutations (both spon-
taneous or chemical/radiation-induced 
“remutations” and multiple constructs 
of targeted mutations involving the 
same gene), often with very different 
phenotypes, are available. Strain and 
mutation symbols, when used cor-
rectly, are critical to the materials and 
methods section of any manuscript, and 
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Mouse gene symbols are shown in 
italics with only the first letter capital-
ized. Symbols for dominant or semi-
dominant spontaneous or chemical/
radiation-induced mutations of uniden-
tified genes are written in the same man-
ner as gene symbols. Recessive allelic 
mutations appear entirely in lowercase. 
Once the previously unknown gene 
has been identified, the allele (muta-
tion) symbol is superscripted, appearing 
immediately after the gene symbol. For 
example, the mouse hairless and rhino 
Jackson mutations are written Hrhr and 
Hrrh7J, respectively. To differentiate them 
from mouse genes, human gene sym-
bols are presented in all capital letters; 
e.g., the human hairless gene symbol is 
HR. For both mice and humans, gene 
and allele names (as opposed to sym-
bols) are written entirely in lowercase 
unless they include a proper noun, as 
with Alstrom syndrome I. Whereas gene 
symbols are italicized, symbols for their 
respective proteins are not. The symbols 
for both mouse and human proteins are 
printed entirely in capital letters.
Specific nomenclature guidance for 
strains, genes, alleles/mutations, and 
chromosomal aberrations can be found 
on the Mouse Genome Informatics 
website via links from the Nomenclature 
Home Page (http://www.informatics.jax.
org/mgihome/nomen/gene.shtml). Strict 
adherence to these nomenclature stan-
dards will allow work to be compared 
fairly and, more important, reviewed 
accurately.
The power of informatics to integrate 
and analyze phenotype and genotype 
data within and across species is con-
tinually increasing, although it is still 
outstripped by the volume of emerging 
data, particularly from the analysis of 
mouse mutants. It is essential that the 
way in which alleles are expressed and 
disease descriptions are captured be 
they help reviewers determine which 
allelic mutation is under investigation, 
enabling them to determine the validity 
of the work being reported.
Mouse (International Committee on 
Standardized Genetic Nomenclature for 
Mice: http://www.informatics.jax.org/mgi 
 home/ nomen/strains.shtml), human (HU 
GO Gene Nomenclature Committee: 
http://www.genenames.org), and rat (Rat 
Gene Nomenclature Committee: http://
rgnc.gen.gu.se/RGNChem.html) nomen-
clature rules are available online. For lab-
oratory mice, names of inbred strains are 
in all capital letters. After a forward slash 
(/) following the strain name, and equally 
important, are the laboratory (investiga-
tor) and institutional codes that designate 
substrains. For example, NOD/ShiLtSzJ 
designates a subline of the nonobese dia-
betic strain originally inbred at Shionogi 
(Shi), in Japan, and later maintained by 
Edward Leiter (Lt), from whose colony a 
subline was initiated by Leonard Shultz 
(Sz). The strain is maintained and dis-
tributed by The Jackson Laboratory (J). 
Abbreviations for commonly used inbred 
strains are also standardized. C57BL/6J 
is abbreviated B6, which is also used 
to refer to mixed or unknown/unspeci-
fied C57BL/6 substrains. B6ByJ refers to 
C57BL/6ByJ and B6EiJ to C57BL/6JEi, 
which, like many other substrains, carry 
unique mutations. In contrast, the BALB/
cJ inbred strain is abbreviated C, and 
BALB/cByJ mice are CBy.
Mixed inbred or incipient congen-
ic strains, in which a mutated gene 
is being transferred from one strain 
background onto another strain, are 
designated by a semicolon between 
the strain abbreviations (e.g., B6;129), 
followed by a hyphen and the mutant 
gene symbol. This nomenclature, indi-
cating a segregating background, is 
in sharp contrast to congenic strain 
names, in which the semicolon is 
replaced by a period to indicate that 
the congenic procedure has been com-
pleted (10 backcrosses, N10, onto the 
new strain, e.g., B6.129). Six backcross 
generations (N6; incipient congenic) 
are commonly accepted by many jour-
nals as adequate, and many mouse dis-
tributors use congenic nomenclature at 
N5; however, speed congenic technol-
ogy has demonstrated that this is not 
optimal (Markel et al., 1997).
semantically unambiguous and standard-
ized to allow computational analysis. 
Nonstandard nomenclature is a serious 
barrier to the analysis of large historical 
datasets in which local nomenclature 
and data structure are idiosyncratic. In 
addition, it is becoming a rate-limiting 
step in the analysis of new data, partic-
ularly data published only in the printed 
literature and not uploaded to databas-
es, because failure to use standardized 
termin ology results in ambiguity and 
inaccuracy, which confound text-mining 
tools, resulting in the need for laborious 
and expensive extraction of the data by 
professional curators.
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complexity of the Association 
Between Psoriasis and comorbidities
Tamar Nijsten1 and Marlies Wakkee1
Multiple observational studies have recently demonstrated associations 
between psoriasis and several comorbidities—especially metabolic syndrome 
and cardiovascular disease, and now osteoporosis. It has been hypothesized 
that elevated levels of tumor necrosis factor-α are a biological explanation for 
the observed associations. In this commentary, we discuss the complexity of 
associations between psoriasis and comorbidities, possible residual confounding, 
the limitations of observational studies in proving causality, absolute versus rel-
ative risk differences, and the clinical relevance and possible clinical impact of 
“upgrading” psoriasis to a systemic disease.
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Several observational studies have 
recently demonstrated that psoriasis 
is associated with diseases other than 
psoriatic arthritis, including cardiovas-
cular disease and metabolic syndrome, 
cancer, chronic obstructive pulmonary 
disease, depression, and, in this issue, 
osteoporosis (Mallbris et al., 2004; 
Gelfand et al., 2006a,b; Dreiher et al., 
2008a,b). The trend in scientific litera-
ture and meeting presentations has been 
to “upgrade” psoriasis from a cutaneous 
to a systemic disease. But before we con-
sider accepting this hypothesis, which 
may have a considerable impact on the 
management of patients, the limitations 
of observational study designs and the 
available evidence should be reviewed.
complexity of association
The direct link between psoriasis and 
many of the possibly associated diseases 
is the presence of chronic inflammation 
and, in particular, elevated levels of the 
multifunctional cytokine tumor necrosis 
factor-α . However, several other factors 
may play important roles and confound 
this association (Figure 1). First, psoria-
sis has a major impact on patients’ lives 
and is associated with depressive symp-
toms in a relatively large proportion of 
patients (Stern et al., 2004). Impaired 
health-related quality of life (HRQOL) 
may lead to unhealthy lifestyle behav-
iors such as smoking, alcohol consump-
tion, decreased physical activity, and 
obesity, which are independent risk fac-
tors for many other diseases. Conversely, 
obesity and smoking may increase the 
risk of developing psoriasis (Naldi et al., 
2005; Setty et al., 2007), suggesting that 
these may be primary risk factors for 
several comorbidities and that psoriasis 
is no more than an innocent bystander. 
The presence of psoriatic arthritis may 
further limit patients’ physical function-
ing. In addition, psoriasis therapies (e.g., 
cyclosporine and prolonged topical 
steroid use) may increase the risk of sev-
eral comorbidities (e.g., cardiovascular 
risk and osteoporosis, respectively), and 
other drugs used to treat comorbidi-
ties may induce or exacerbate psoriasis 
(e.g., β-blockers and lithium). In addi-
tion to HRQOL impairment and (prior) 
drug exposure, several epidemiological 
biases may affect the association.
Most importantly, psoriasis patients 
are more likely to visit physicians 
because of their disease than “healthy” 
people from the general popula-
tion, which puts them at risk for being 
screened for and diagnosed with other 
diseases. This detection bias is especial-
ly important in the diagnosis of common 
diseases that are typically underdiag-
nosed, such as hypertension and osteo-
porosis in men (Dreiher et al., 2008a). 
Moreover, most psoriasis patients have 
limited disease (affecting less than one 
palm-sized area; Stern et al., 2004), 
and patients who seek medical care 
for their limited psoriasis are probably 
also more likely to seek care sooner for 
